Venetoclax for CLL: Real-World Data on Safety & Efficacy
- Venetoclax (Venclexta; Abbvie and Genentech) therapy demonstrates comparable efficacy and safety in patients with chronic lymphocytic leukemia (CLL) in real-world (RW) settings as observed in clinical trials, according...
- The study, published in Advances in Hematology1, adds to a growing body of evidence supporting the use of targeted therapies like venetoclax in CLL.
- The phase 3 MURANO trial (NCT02005471) demonstrated the benefits of venetoclax in combination with rituximab (Rituxan; Genentech and Biogen).
Okay, here’s a draft article based on the provided text, adhering to all the specified requirements (E-A-T, components, self-check). I’ve aimed for a Google News-amiable tone – informative, clear, and avoiding sensationalism. I’ve also included the requested HTML elements.
“`html
Real-World Data Confirms Venetoclax Efficacy and Safety in CLL
Table of Contents
Venetoclax (Venclexta; Abbvie and Genentech) therapy demonstrates comparable efficacy and safety in patients with chronic lymphocytic leukemia (CLL) in real-world (RW) settings as observed in clinical trials, according to a recent study. The research also indicates that tumor lysis syndrome (TLS) did not present a significant clinical challenge in routine clinical practice.
The study, published in Advances in Hematology1, adds to a growing body of evidence supporting the use of targeted therapies like venetoclax in CLL. Over the past decade, these therapies have proven superior to chemoimmunotherapy for many patients.
Venetoclax’s Proven Track Record
The phase 3 MURANO trial (NCT02005471) demonstrated the benefits of venetoclax in combination with rituximab (Rituxan; Genentech and Biogen). The trial showed that patients receiving venetoclax and rituximab achieved a 2-year progression-free survival rate of 84.9%, substantially higher than the 36.3% rate observed in the rituximab-bendamustine group.2
However, clinical trials often have strict inclusion criteria, limiting the generalizability of their findings. Real-world studies, by contrast, capture data from more diverse patient populations, providing a more realistic assessment of a therapy’s performance in everyday clinical practice.
“As venetoclax has emerged as a pivotal treatment for CLL, the demand for RW evidence to validate its efficacy and safety has grown significantly,” the authors wrote.
Study Details
The investigators retrospectively analyzed medical records of patients with CLL or small lymphocytic lymphoma (SLL) treated with venetoclax at Zealand University Hospital in Denmark between April 2017 and January 2023. All participants were at least 18 years old. patients with confirmed Richter transformation before starting venetoclax were excluded.
| Study Parameter | Details |
|---|